Pain Management Therapeutics Market

Transparency Market Research is Published new Market Report “Pain Management Therapeutics Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," in 2011, the global pain management therapeutics market was valued at USD 40.93 billion and is expected to decline at a CAGR of (5.5%) from 2012 to 2018, to reach an estimated value of USD 29.47 billion in 2018.

The global pain management therapeutics market is expected to experience a decline in revenues at a CAGR of (5.5%) during the forecast period, mainly due to patent expirations of the leading branded drugs. Although the global incidence rates of cancer, diabetes and other debilitating diseases that cause various chronic pain conditions is on a rise, the decline in market revenue is inevitable due to generic incursion for the top pain management drugs. Moreover, lack of a strong pipeline of novel or combination drugs that could help restore the positive growth of the overall market is also expected to contribute to the overall decline in the global pain management therapeutics market.

Administration of analgesics is the first line of treatment for the management of acute as well as chronic pain conditions. Some of the factors driving the growth of this market

include the favorable regulatory and healthcare reforms such as the U.S. Patient Protection and Affordable Care Act of 2010. Also, the economic and effective nature of treatment with therapeutics compared to other modes, such as neurostimulation devices and acupuncture, will continue to fuel the uptake of drugs in pain management.

The market for non-steroidal anti-inflammatory drugs (NSAIDs) accounted for the largest share by revenue in 2011, of the total pain management therapeutics market by therapeutic class. This class comprises of some of the oldest known painkillers such as diclofenac, ibuprofen and Aspirin (acetylsalicylic acid) which are now commonly available as over-the-counter (OTC) medications, globally. However, the patent expiry of Celebrex (celecoxib) in 2013 is expected to negatively impact the market with a decline in revenues post patent expiry. The class of other non-narcotic analgesics consists of acetaminophen, sold as OTC drugs in the names of Tylenol, Panadol and Excedrin, and is expected to record the highest CAGR of 3.1% during the forecast period. Increase in the uptake of OTC drugs across the globe to overcome common pain conditions such as headache and body ache, will be responsible for this growth. The loss of patent exclusivity of other key brands such as Cymbalta (duloxetine), OxyContin (oxycodone) and Lidoderm (lidocaine) scheduled in the year 2013 will have a profound impact on the growth of the overall market.

North America was the largest regional market by revenue in 2011, due to the presence of one or more branded drugs belonging to each therapeutic class. However, the region is expected to record the lowest CAGR due to the looming patent expiries of these brands.

The market for generic formulations accounted for a larger share of the overall pain management therapeutics market in 2011, as against branded formulations. The market for branded pharmaceuticals was highly fragmented in 2011, with Pfizer, Inc., Purdue Pharma LP and Eli Lilly & Co. contributing to over 80% of the total market revenue. Other important players in this market include Endo Health Solutions, AstraZeneca PLC, Johnson & Johnson, and Merck & Co., Inc.

The pain management therapeutics market is segmented as follows:

Pain Management Therapeutics Market, by Therapeutic Class

• Anticonvulsants
• Antidepressants
• Anesthetics
• NSAIDs
• Opioids
• Other Non-Narcotic Analgesics (Acetaminophen)

• Anti-Migraine Agents

Pain Management Therapeutics Market, by Indication

• Neuropathic Pain
• Fibromyalgia
• Arthritic Pain, by Type
• Osteoarthritis
• Rheumatoid Arthritis
• Chronic Back Pain
• Migraine
• Post-operative Pain
• Cancer Pain

Pain Management Therapeutics Market, by Geography

• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

TABLE OF CONTENTS :

Chapter 1 Preface

1.1 Report Description

1.2 Market Segmentation

1.3 Research Methodology

Chapter 2 Executive Summary

Browse the full report at  http://www.transparencymarketresearch.com/pain-management-therapeutics.html

Chapter 3 Market Overview

3.1 Introduction to Pain Management – Types of Treatments

3.2 World Health Organization’s “Pain Ladder” for cancer

3.3 Market Trends and Future Outlook

       3.3.1 Impact of generics

       3.3.2 Key patent expirations

3.4 Market Drivers

       3.4.1 Global increasing incidence of chronic pain disorders

       3.4.2 Favorable regulatory scenario and healthcare reforms

       3.4.3 Easy and effective medications

       3.4.4 Impact analysis of market drivers

3.5 Market Restraints

       3.5.1 Prescription drug abuse

       3.5.2 Pain advocacy groups losing power, influence and funding

       3.5.3 Adulteration and fake drugs thrive in developing regions

       3.5.4 Long term pain relief from surgical procedures, alternative therapies and medical devices

       3.5.5 Impact analysis of market restraints

3.6 Market Opportunities

       3.6.1 Novel molecule combinations and drug delivery techniques are expected to become a rising opportunity in forecast period

       3.6.2 Generics expected to be a rising opportunity globally

 3.7 Porter’s Five Forces Analysis

       3.7.1 Bargaining power of buyers

       3.7.2 Bargaining power of suppliers

       3.7.3 Threat of substitutes

       3.7.4 Threat of new entrants

       3.7.5 Competitive rivalry

3.8 Market Attractiveness Analysis: Global Pain Management Therapeutics Market, By Geography (2011)

Chapter 4 Global Pain Management Therapeutics Market, by Therapeutic Class

4.1 Anticonvulsants

       4.1.1 Current and future market scenario

4.2 Antidepressants

       4.2.1 Current market scenario and patent expiry effect

       4.2.2 Future market scenario

4.3 Anesthetics

       4.3.1 Current market scenario and patent expiry effect

       4.3.2 Pipeline drugs and their effect

       4.3.3 General Anesthetics

       4.3.4 Local Anesthetics

4.4 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

       4.4.1 Current market scenario and patent expiry effect

4.5 Opioids

       4.5.1 Current market scenario and patent expiry effect

       4.5.2 Pipeline drugs and their effect on the market

                4.5.2.1 MoxDuo IR

               

              4.5.2.2 Remoxy

4.6 Anti-Migraine Agents

       4.6.1 Pipeline drugs and additional approvals

4.7 Other Non-Narcotic Analgesics (Acetaminophen)

Chapter 5 Global Pain Management Therapeutics Market, by Indication

5.1 Neuropathic Pain

5.2 Fibromyalgia

5.3 Arthritic Pain

       5.3.1 Osteoarthritis (OA)

       5.3.2 Rheumatoid Arthritis (RA)

5.4 Chronic Back Pain

5.5 Migraine

5.6 Post-operative pain

5.7 Cancer Pain

Chapter 6 Global Pain Management Therapeutics Market, by Geography

6.1 Overview

       6.1.1 Global Pain Management Therapeutics Market, by Geography, Size and Forecast, 2010 – 2018 (USD Million)

       6.1.2 Comparative Analysis: Global Pain Management Therapeutics Market, by Geography, 2011 & 2018 (Value %)

6.2 North America

       6.2.1 North America Pain Management Therapeutics  Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)

6.3 Europe

       6.3.1 Europe Pain Management Therapeutics  Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)

6.4 Asia-Pacific

       6.4.1 Asia-Pacific Pain Management Therapeutics  Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)

6.5 Rest of the World (RoW)

       6.5.1 RoW Pain Management Therapeutics Market, by Therapeutic Class, Size and 

Forecast, 2010 - 2018 (USD Million)

Chapter 7 Competitive Landscape

7.1 Market Share Analysis: Global Pain Management Therapeutics Market (2011)

       7.1.1 Market Share by Marketing Status (Branded & Generic Pharmaceuticals), 2011 (%)

       7.1.2 Market Share by Key Players: Branded Pharmaceuticals, 2011 (%)

7.2 Pipeline Snapshot: Pain Management Therapeutics

       7.2.1 MoxDuo (morphine and oxycodone)

       7.2.2 Remoxy (oxycodone)

       7.2.3 Posidur (SABER-bupivacaine)

       7.2.4 Zecuity (transdermal sumatriptan)

Chapter 8 Recommendations

8.1 Development of novel combination formulations

8.2 Addressing unmet needs: drug abuse and side-effects

8.3 Generics manufacturers: Investment in emerging markets such as India, China and Russia

8.4 Mergers and acquisitions to enter or strengthen market presence

Chapter 9 Company Profiles

9.1 Abbott Laboratories

       9.1.1 Company Overview

       9.1.2 Financial Overview

       9.1.3 Product Portfolio

       9.1.4 Business Strategies

       9.1.5 Recent Developments

9.2 Allergan, Inc.

       9.2.1 Company Overview

       9.2.2 Financial Overview

       9.2.3 Product Portfolio

       9.2.4 Business Strategies

       9.2.5 Recent Developments

9.3 Covidien plc

       9.3.1 Company Overview

       9.3.2 Financial Overview

       9.3.3 Product Portfolio

       9.3.4 Business Strategies

       9.3.5 Recent Developments

9.4 Durect Corporation

       9.4.1 Company Overview

       9.4.2 Financial Overview

       9.4.3 Pipeline Products

       9.4.4 Business Strategies

       9.4.5 Recent Developments

9.5 Eli Lilly and Company

       9.5.1 Business Overview

       9.5.2 Financial Overview

       9.5.3 Product Portfolio

       9.5.4 Business Strategies

       9.5.5 Recent Developments

9.6 Endo Health Solutions, Inc.

       9.6.1 Company Overview

       9.6.2 Financial Overview

       9.6.3 Product Portfolio

       9.6.4 Business Strategies

       9.6.5 Recent Developments

9.7 Forest Laboratories, Inc.

       9.7.1 Company Overview

       9.7.2 Financial Overview

       9.7.3 Product Portfolio

       9.7.4 Business Strategies

       9.7.5 Recent Developments

9.8 GlaxoSmithKline plc

       9.8.1 Company Overview

       9.8.2 Financial Overview

       9.8.3 Product Portfolio

       9.8.4 Business Strategies

       9.8.5 Recent Developments

9.9 Hospira, Inc.

       9.9.1 Company Overview

       9.9.2 Financial Overview

       9.9.3 Product Portfolio

       9.9.4 Business Strategies

       9.9.5 Recent Developments

9.10 Johnson & Johnson

       9.10.1 Company Overview

       9.10.2 Financial Overview

       9.10.3 Product Portfolio

       9.10.4 Business Strategies

       9.10.5 Recent Developments

9.11 Merck & Co., Inc.

       9.11.1 Company Overview

       9.11.2 Financial Overview

       9.11.3 Product Portfolio

       9.11.4 Business Strategies

       9.11.5 Recent Developments

9.12 Mundipharma International Ltd.

       9.12.1 Company Overview

       9.12.2 Financial Overview

       9.12.3 Product Portfolio

       9.12.4 Business Strategies

       9.12.5 Recent Developments

9.13 Novartis  International AG

       9.13.1 Company Overview

       9.13.2 Financial Overview

       9.13.3 Product Portfolio

       9.13.4 Business Strategies

       9.13.5 Recent Developments

9.14 NuPathe, Inc.

       9.14.1 Company Overview

       9.14.2 Financial Overview

       9.14.3 Product Portfolio

       9.14.4 Business Strategies

       9.14.5 Recent Developments

9.15 Pain Therapeutics, Inc.

       9.15.1 Company Overview

       9.15.2 Financial Overview

       9.15.3 Product Portfolio

       9.15.4 Business Strategies

       9.15.5 Recent Developments

9.16 Pfizer, Inc.

       9.16.1 Company Overview

       9.16.2 Financial Overview

       9.16.3 Product Portfolio

       9.16.4 Business Strategies

       9.16.5 Recent Developments

9.17 Purdue Pharma L.P.

       9.17.1 Company Overview

       9.17.2 Financial Overview

       9.17.3 Product Portfolio

       9.17.4 Business Strategies

       9.17.5 Recent Developments

9.18 QRx Pharma Ltd.

       9.18.1 Company Overview

       9.18.2 Financial Overview

       9.18.3 Product Portfolio

       9.18.4 Business Strategies

       9.18.5 Recent Developments

9.19 Sanofi

       9.19.1 Company Overview

       9.19.2 Financial Overview

       9.19.3 Product Portfolio

       9.19.4 Business Strategies

       9.19.5 Recent Developments

9.20 Teva Pharmaceutical Industries Limited

       9.20.1 Company Overview

       9.20.2 Financial Overview

       9.20.3 Product Portfolio

       9.20.4 Business Strategies

       9.20.5 Recent Developments

9.21 UCB (Union Chemnique Belge) S.A.

       9.21.1 Company Overview

       9.21.2 Financial Overview

       9.21.3 Product Portfolio

       9.21.4 Business Strategies

       9.21.5 Recent Developments

About Us:

Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.

We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.